Erasca, Inc.
(ERAS - NASDAQ)
19,71 USD
📋 Profilo Aziendale

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

|